Kenya - English - Pharmacy and Poisons Board

glaxosmithkline pharmaceutical kenya limited likoni rd industrial area p.o box 78392 - zidovudine - oral solution - 10mg/ml - antivirals for systemic use:

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline s.a (pty) ltd - zidovudine, lamivudine - combination of dossage forms - zidovudine capsules 100mg, lamivudine tablets 150mg

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline s.a (pty) ltd - zidovudine - infusion - zidovudine intravenous infusion 200mg/20ml

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline s.a (pty) ltd - zidovudine - syrup - zidovudine syrup 50mg/5ml

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

viiv healthcare k.k. - zidovudine - white (opaque)/white (opaque) capsule

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - efavirenz - film coated tablets - efavirenz 600 mg - efavirenz - efavirenz - stocrin in combination with other antiretroviral agents, is indicated for the treatment of hiv-1-infection .

Israel - English - Ministry of Health

j-c health care ltd - etravirine - tablets - etravirine 100 mg - etravirine - etravirine - intelence is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-experienced adult patients including those with non-nucleoside reverse transcriptase inhibitor (nnrti) resistance. treatment history and when available resistance testing should guide the use of intelence. in patients who have experienced virological failure on an nnrti- and nucleoside or nucleotide reverse transcriptase inhibitor (n[t]rti) - containing regimen intelence is not recommended for use in combination with n(t)rtis only.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg) - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; macrogol 3000; croscarmellose sodium; silicon dioxide; magnesium stearate; povidone; polysorbate 20; titanium dioxide; triacetin; microcrystalline cellulose - edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naive adult patients with viral load less than or equal to 100,000 copies/ml at baseline. this indication is based on week 48 safety and efficacy analyses from 2 randomised double-blind, controlled phase iii trials in treatment-naive adult patients and on week 96 safety and efficacy analyses from the phase iib trial tmc278-c204 in treatment-naive adult patients (see clinical trials section).

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - darunavir - film coated tablets - darunavir 800 mg - darunavir - darunavir teva co-administered with 100 mg ritonavir and with other antiretroviral agents,is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for patients over 18 years of age.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 10 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg